Literature DB >> 17571070

Diagnosing model diagnostics.

M O Karlsson1, R M Savic.   

Abstract

Conclusions from clinical trial results that are derived from model-based analyses rely on the model adequately describing the underlying system. The traditionally used diagnostics intended to provide information about model adequacy have seldom discussed shortcomings. Without an understanding of the properties of these diagnostics, development and use of new diagnostics, and additional information pertaining to the diagnostics, there is risk that adequate models will be rejected and inadequate models accepted. Thus, a diagnosis of available diagnostics is desirable.

Mesh:

Year:  2007        PMID: 17571070     DOI: 10.1038/sj.clpt.6100241

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  210 in total

1.  Population pharmacokinetic model of transdermal nicotine delivered from a matrix-type patch.

Authors:  Matthew W Linakis; Joseph E Rower; Jessica K Roberts; Eleanor I Miller; Diana G Wilkins; Catherine M T Sherwin
Journal:  Br J Clin Pharmacol       Date:  2017-09-06       Impact factor: 4.335

2.  Population pharmacokinetics modeling of levetiracetam in Chinese children with epilepsy.

Authors:  Ying-hui Wang; Li Wang; Wei Lu; De-wei Shang; Min-ji Wei; Ye Wu
Journal:  Acta Pharmacol Sin       Date:  2012-06       Impact factor: 6.150

3.  Population pharmacokinetic and pharmacodynamic model-based comparability assessment of a recombinant human Epoetin Alfa and the Biosimilar HX575.

Authors:  Xiaoyu Yan; Philip J Lowe; Martin Fink; Alexander Berghout; Sigrid Balser; Wojciech Krzyzanski
Journal:  J Clin Pharmacol       Date:  2011-12-12       Impact factor: 3.126

4.  Automatic data binning for improved visual diagnosis of pharmacometric models.

Authors:  Marc Lavielle; Kevin Bleakley
Journal:  J Pharmacokinet Pharmacodyn       Date:  2011-10-26       Impact factor: 2.745

5.  Integrated population pharmacokinetic analysis of voriconazole in children, adolescents, and adults.

Authors:  Lena E Friberg; Patanjali Ravva; Mats O Karlsson; Ping Liu
Journal:  Antimicrob Agents Chemother       Date:  2012-03-19       Impact factor: 5.191

6.  A semi-mechanistic modeling strategy to link in vitro and in vivo drug release for modified release formulations.

Authors:  Martin Bergstrand; Erik Söderlind; Ulf G Eriksson; Werner Weitschies; Mats O Karlsson
Journal:  Pharm Res       Date:  2011-09-27       Impact factor: 4.200

7.  Implementation and evaluation of the SAEM algorithm for longitudinal ordered categorical data with an illustration in pharmacokinetics-pharmacodynamics.

Authors:  Radojka M Savic; France Mentré; Marc Lavielle
Journal:  AAPS J       Date:  2010-11-11       Impact factor: 4.009

8.  A simultaneous analysis of the time-course of leukocytes and neutrophils following docetaxel administration using a semi-mechanistic myelosuppression model.

Authors:  Angelica Linnea Quartino; Lena E Friberg; Mats O Karlsson
Journal:  Invest New Drugs       Date:  2010-12-14       Impact factor: 3.850

9.  Two bootstrapping routines for obtaining imprecision estimates for nonparametric parameter distributions in nonlinear mixed effects models.

Authors:  Paul G Baverel; Radojka M Savic; Mats O Karlsson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2010-11-13       Impact factor: 2.745

10.  Evaluation of Concomitant Antiretrovirals and CYP2C9/CYP2C19 Polymorphisms on the Pharmacokinetics of Etravirine.

Authors:  Bruce Green; Herta Crauwels; Thomas N Kakuda; Simon Vanveggel; Anne Brochot
Journal:  Clin Pharmacokinet       Date:  2017-05       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.